In a groundbreaking discovery that could reshape our understanding of renal pathophysiology, researchers have identified a pivotal molecular mechanism linking endothelial cell death to the progression of kidney injury. The enzyme USP35, a deubiquitinase, has been unveiled as a key regulator that influences the stability of MDM4, thereby modulating a form of programmed cell death known as ferroptosis in endothelial cells. This revelation not only deepens insight into cellular death pathways but also opens novel therapeutic avenues for combating renal diseases characterized by vascular dysfunction and tissue damage.
Endothelial cells, which line the interior surface of blood vessels, play an indispensable role in maintaining vascular homeostasis and organ function. In the kidneys, these cells are especially critical for regulating filtration and nutrient exchange, processes that are highly susceptible to oxidative stress and inflammation. Ferroptosis, a recently described iron-dependent form of regulated cell death, is characterized by the accumulation of lipid peroxides and reactive oxygen species, factors that compromise membrane integrity and cellular viability. The elucidation of mechanisms governing endothelial ferroptosis is therefore vital for understanding vascular contributions to renal injury.
At the heart of this novel mechanism is USP35, an enzyme known for its ability to remove ubiquitin moieties from target proteins, thereby regulating their degradation via the proteasome. The study reveals that USP35 directly interacts with MDM4, a protein previously notorious for its role in modulating the tumor suppressor p53. MDM4’s stability is crucial because it influences cellular stress responses and survival. By stabilizing MDM4 through deubiquitination, USP35 effectively restricts its degradation, thus altering downstream signaling pathways that culminate in endothelial ferroptosis.
This newly discovered pathway illustrates how the delicate balance between ubiquitination and deubiquitination controls the fate of endothelial cells under stress conditions. When USP35 activity is heightened, MDM4 levels increase, tipping the scales towards enhanced ferroptotic death. This ferroptosis in endothelial cells compromises the vascular barrier, escalating inflammation and fostering a microenvironment conducive to renal tissue damage and progression of injury. The direct link between USP35 activity and ferroptosis offers an unprecedented molecular target for therapeutic intervention.
The implications for renal pathology are profound. Chronic kidney diseases (CKD) and acute kidney injury (AKI) often involve vascular endothelial dysfunction and cell death, yet the underlying molecular players have remained elusive. By demonstrating that USP35 regulates MDM4 degradation to promote endothelial ferroptosis, this research fills a critical knowledge gap. It suggests that modulating USP35 activity could stabilize endothelial integrity, reduce ferroptotic cell death, and thereby slow or halt the progression of renal injury.
From a biochemical perspective, the modulation of MDM4 by USP35 adds a layer of complexity to ubiquitin-proteasome dynamics in endothelial cells. The ubiquitin-proteasome system is key in maintaining proteostasis, and aberrations in this system can precipitate pathological states. By removing ubiquitin chains from MDM4, USP35 prevents its proteasomal degradation, leading to an accumulation of MDM4 and an altered cellular response to oxidative stress and iron-induced lipid peroxidation. This fine-tuned molecular interplay underscores the sophistication of cellular regulatory networks.
Further, this research sheds light on the cross-talk between ferroptosis and the p53 signaling axis. MDM4 is a known negative regulator of p53, a master regulator of cell cycle and apoptosis. By safeguarding MDM4 from degradation, USP35 indirectly modulates p53 activity, influencing endothelial cell destiny amid oxidative challenges. This connection elucidates how various death pathways interconnect and suggests that targeting USP35 could have multifaceted effects on cell survival and death decisions.
Experimental models employed in the study demonstrated that genetic or pharmacological inhibition of USP35 resulted in decreased MDM4 levels, reduced endothelial ferroptosis, and attenuated renal injury. These findings not only confirm the causal role of USP35 in driving vascular cell death but also highlight the potential of USP35 inhibitors as promising candidates for drug development. Such targeted therapy could preserve kidney function by maintaining endothelial health and preventing the cascade of inflammatory and fibrotic responses.
Notably, the vascular endothelium is an attractive therapeutic target because it is both accessible to circulating drugs and instrumental in modulating systemic inflammation and organ homeostasis. By pinpointing USP35 as a molecular fulcrum influencing ferroptosis, the study opens up prospects for precision medicine approaches tailored to the vascular component of renal diseases. Future clinical studies will be necessary to translate these findings into viable treatment regimens.
Moreover, the broader implications extend beyond nephrology. Endothelial dysfunction and ferroptosis are implicated in a variety of pathological conditions, including atherosclerosis, stroke, and cancer. Understanding how USP35 modulates endothelial cell fate could inform therapeutic strategies across diverse diseases marked by oxidative stress and aberrant cell death. The concept of targeting deubiquitinases to control ferroptosis represents an exciting frontier in biomedical research.
This research also underscores the importance of ubiquitin editing in maintaining cellular equilibrium under stress. The precise regulation of protein degradation determines whether cells adapt, survive, or succumb to injury. USP35 emerges from this study as a decisive switch, dictating the delicate balance in endothelial cells between survival and ferroptotic demise, highlighting the intricacies of post-translational modifications in pathophysiological processes.
In summary, the discovery of the USP35-MDM4 axis as a regulator of endothelial ferroptosis provides a molecular framework that links ubiquitin-proteasome biology to vascular cell death and renal injury progression. The identification of USP35 as a linchpin in this pathway propels forward our understanding of ferroptosis regulation and sets the stage for innovative therapeutic strategies aimed at preserving kidney function and enhancing patient outcomes.
Ongoing investigations are now centered on developing selective USP35 inhibitors with favorable pharmacokinetic properties and minimal off-target effects. Concurrently, researchers are delving deeper into the structural biology of USP35-MDM4 interactions, which could yield insights for designing next-generation molecules capable of modulating this pathway with high specificity. This dual approach of mechanistic elucidation and drug discovery signifies a comprehensive strategy to translate basic science findings into clinical interventions.
As the field evolves, integrating these molecular insights with patient-derived data and clinical parameters will be crucial. Biomarkers reflecting USP35 activity or endothelial ferroptosis could emerge as diagnostic tools to stratify patients at risk and monitor therapeutic responses. Such personalized medicine frameworks could revolutionize the management of renal and vascular diseases.
The revelation of USP35’s role in endothelial ferroptosis not only advances the frontiers of cell death research but also rekindles hope for effective treatments for renal injury—a condition with significant morbidity and mortality worldwide. As this exciting story unfolds, the scientific community eagerly anticipates further breakthroughs that might change the landscape of renal therapeutics forever.
Subject of Research: Regulation of endothelial ferroptosis and renal injury progression via USP35-mediated MDM4 degradation.
Article Title: Deubiquitinase USP35 regulates MDM4 degradation to promote endothelial ferroptosis and renal injury progression.
Article References:
Han, C., Guo, L., Li, W. et al. Deubiquitinase USP35 regulates MDM4 degradation to promote endothelial ferroptosis and renal injury progression. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03128-5
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41420-026-03128-5
Tags: deubiquitinase enzymes in kidney diseaseendothelial cell ferroptosisendothelial dysfunction in kidney diseaseferroptosis in renal injuryiron-dependent cell death mechanismslipid peroxidation in kidney cellsMDM4 regulation by USP35molecular pathways of ferroptosisoxidative stress in endothelial cellstherapeutic targets for renal vascular damageUSP35 role in kidney damagevascular contributions to renal pathology
